Ronald Nahass

Dr. Ronald Nahass

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 September 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Luigi BrunettiLuigi Brunetti
Luigi Brunetti
ODOumou Diawara
Oumou Diawara
ATAndrew Tsai
Andrew Tsai
Bonnie FiresteinBonnie Firestein
Bonnie Firestein
RNRonald Nahass
Ronald Nahass
NSNaomi Schlesinger
Naomi Schlesinger
The repurposing of colchicine for the treatment of COVID-19 was suggested based in its immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a single-center propensity score matched cohort study, including all consecutive COVID-19 patients admitted to a community hospital between 1 March 2020 and 30 May 2020. Patients were stratified according to the receipt of colchicine. The primary endpoint was defined as in-hospital death within 28-days follow-up. Secondary endpoints included favorable change in the Ordinal Scale for Clinical Improvement on days 14 and 28 versus baseline, proportion of patients not requiring supplemental oxygen on days 14 and 28, and proportion of patients discharged by day 28. In total data for 303 PCR positive COVID-19 patients were extracted and 66 patients were included in the 1:1 matched cohort study. At the end of the 28 day follow-up, patients receiving colchicine were approximately five times more likely to be discharged (odds ratio, 5.0; 95% confidence interval, 1.25–20.1; p = 0.023) and when comparing mortality, there were 3 deaths (9.1%) in patients receiving colchicine versus 11 deaths (33.3%) in the groups receiving standard of care (odds ratio, 0.20; 95% confidence interval, 0.05–0.80; p = 0.023). These observations warrant further investigation in large controlled clinical trials.

27 June 2018 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
BWBenjamin Y. Winer
Benjamin Y. Winer
ESElham Shirvani-Dastgerdi
Elham Shirvani-Dastgerdi
YBYaron Bram
Yaron Bram
JSJulie Sellau
Julie Sellau
BLBenjamin E. Low
Benjamin E. Low
Alexander PlossAlexander Ploss
Alexander Ploss
An inbred mouse model for HDV infection can be used to study virally induced immune responses and for testing antiviral therapeutics.

20 April 2022 in Journal of Hepatology
Verified
Journal Article
Open access
MYMan-Fung Yuen
Man-Fung Yuen
KAKosh Agarwal
Kosh Agarwal
XMXiaoli Ma
Xiaoli Ma
TNTuan T. Nguyen
Tuan T. Nguyen
ESEugene R. Schiff
Eugene R. Schiff
MSMark S. Sulkowski
Mark S. Sulkowski
HBV nucleos(t)ide reverse transcriptase inhibitors (NrtIs) do not completely suppress HBV replication. Previous reports indicate persistent viremia during NrtI treatment despite HBV DNA being undetectable. HBV core inhibitors may enhance viral suppression when combined with NrtIs. This phase II trial (NCT03576066) evaluated the efficacy and safety of the investigational core inhibitor, vebicorvir (VBR), in virologically- suppressed patients on NrtIs. Non-cirrhotic, NrtI-suppressed patients with chronic HBV were randomised to VBR 300 mg once daily or matching placebo (PBO) for 24 weeks. Treatment was stratified by hepatitis B e antigen (HBeAg) status. The primary endpoint was change from Baseline in serum HBeAg or hepatitis B surface antigen (HBsAg) after 24 weeks. Of 73 patients enrolled, 47 were HBeAg positive and 26 were HBeAg negative. In HBeAg-positive and -negative patients, there were no differences in the change from Baseline at Week 24 for HBsAg or HBeAg. Using a novel, high-sensitivity assay to detect HBV DNA, a greater proportion of patients with detectable HBV DNA at Baseline achieved undetectable HBV DNA at Week 24 in the VBR+NrtI vs. PBO+NrtI group. In HBeAg-positive patients, a greater change from Baseline in HBV pregenomic (pg)RNA was observed at Week 24 with VBR+NrtI vs. PBO+NrtI. Treatment-emergent adverse events (TEAEs) in VBR+NrtI patients included upper respiratory tract infection, nausea, and pruritus. No serious adverse events, Grade 4 TEAEs, or deaths were reported. In this 24-week study, VBR+NrtI demonstrated a favourable safety and tolerability profile. While there were no significant changes in viral antigen levels, enhanced viral suppression was demonstrated by greater changes in DNA and pgRNA with the addition of VBR compared to NrtI alone. NCT03576066. Core inhibitors represent a novel approach for the treatment of chronic hepatitis B virus (HBV) infection, with mechanisms of action distinct from existing treatments. In this study, vebicorvir added to existing therapy reduced HBV replication to a greater extent than existing treatment and was generally safe and well tolerated.

1 February 2026 in Annals of Internal Medicine
Verified
Journal Article
Closed access
ACAmy E. Colson
Amy E. Colson
GCGordon E. Crofoot
Gordon E. Crofoot
PRPeter J. Ruane
Peter J. Ruane
MRMoti N. Ramgopal
Moti N. Ramgopal
ADAlexandra W. Dretler
Alexandra W. Dretler
JEJoseph J. Eron
Joseph J. Eron
Once-weekly oral islatravir plus lenacapavir (ISL+LEN) has the potential to address adherence challenges with daily HIV-1 treatment. To evaluate efficacy and safety of once-weekly ISL+LEN. Phase 2, randomized, open-label, active-controlled study. (ClinialTrials.gov: NCT05052996). 44 U.S. sites. Adults with HIV-1 RNA viral load of less than 50 copies/mL receiving daily bictegravir, emtricitabine, and tenofovir alafenamide combination (B/F/TAF) for 24 weeks or more. Once-weekly oral ISL, 2 mg, plus LEN, 300 mg, or daily oral B/F/TAF. Proportion with HIV-1 RNA viral load of 50 copies/mL or more at week 24 (primary end point; U.S. Food and Drug Administration Snapshot Algorithm). Secondary end points: proportion of participants with HIV-1 RNA viral load of 50 copies/mL or more (weeks 12 and 48) and HIV-1 RNA viral load of less than 50 copies/mL (weeks 12, 24. and 48), safety, and CD4+ T-cell and lymphocyte count changes (weeks 12, 24, and 48). A total of 104 participants were randomly assigned and treated (n = 52 per group). At week 24, one ISL+LEN participant and no B/F/TAF participants had HIV-1 RNA viral load of 50 copies/mL or more (difference, 1.9% [95% CI, -5.2% to 10.5%]); 94.2% of participants in both groups had HIV-1 RNA viral load of less than 50 copies/mL (difference, 0% [CI, -10.9% to 10.9%]). At week 48, 94.2% and 92.3% of ISL+LEN and B/F/TAF participants, respectively, had HIV-1 RNA viral load of less than 50 copies/mL (difference, 1.9% [CI, -9.3% to 13.6%]); no participant had HIV-1 RNA viral load of 50 copies/mL or more. Two ISL+LEN participants discontinued treatment (before week 24) due to adverse events (AEs) unrelated to the study drug. No AEs that were grade 3 or greater or serious were related to treatment in either group. Changes in CD4+ T-cell and lymphocyte counts from baseline to week 48 were similar between groups, with no discontinuations of study drug treatment due to decreased CD4+ T cells or lymphocytes. Open-label, modest sample size, and only U.S.-based participants. Once-weekly oral ISL+LEN maintained high rates of virologic suppression through week 48 and was not associated with any treatment-related grade 3 or greater or serious AEs. Gilead Sciences, Inc.

1 September 2022 in Annals of Internal Medicine
Verified
Journal Article
Closed access
JGJason Grebely
Jason Grebely
GDGregory J. Dore
Gregory J. Dore
FAFrederick L. Altice
Frederick L. Altice
BCBrian Conway
Brian Conway
ALAlain H. Litwin
Alain H. Litwin
HPHeather Platt
Heather Platt
Direct-acting antiviral medications are highly effective in inducing sustained virologic response in patients with chronic hepatitis C infection. However, there are concerns that this benefit may b... Visual Reinfection After Treatment of HCV Infection. Direct-acting antiviral medications are highly effective in inducing sustained virologic response in patients with chronic hepatitis C ... Background: Hepatitis C virus (HCV) reinfection after successful treatment may reduce the benefits of cure among people who inject drugs. Objective: To evaluate the rate of HCV reinfection for 3 ye...

5 November 2020 in Pharmacy
Verified
Journal Article
Open access
PDF file
THThomas Hong
Thomas Hong
JGJimmy Gonzalez
Jimmy Gonzalez
RNRonald Nahass
Ronald Nahass
Luigi BrunettiLuigi Brunetti
Luigi Brunetti
Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused significant health and economic havoc around the globe. One of the early agents targeted for repurposing to treat and prevent COVID-19 was hydroxychloroquine (HCQ). In this systematic review and meta-analysis, HCQ is evaluated for its potential role in decreasing mortality in hospitalized patients with COVID-19. We searched PubMed, Web of Science, and medRxiv databases using combinations of the terms “COVID-19”, “SARS-CoV-2”, “coronavirus”, “hydroxychloroquine”, and “mortality”. Articles were selected for further review based on the content of their abstracts. Studies were excluded if they were of poor methodological quality, were not based in the inpatient setting, or did not have available data to assess the primary outcome of death between patients treated with HCQ versus standard of care. Once the final dataset was compiled, a meta-analysis using the random-effects model was performed. Our search identified 14 studies involving 24,780 patients of whom 12,707 patients were on HCQ alone or in combination with other adjuvant therapies. HCQ alone or in combination with other drugs did not significantly decrease mortality in hospitalized patients with COVID-19 (odds ratio [OR], 0.95; 95% CI, 0.72–1.26; p = 0.732; I2 = 91.05). Similar findings were observed in all subgroup analyses. HCQ did not significantly impact mortality in hospitalized patients with COVID-19. Additional well-designed studies are essential due to the heterogeneity in available studies.